Toulouse, France
Toulouse, France

Time filter

Source Type

Elior Group (Paris:ELIOR) (Euronext Paris – ISIN: FR 0011950732), one of the world’s leading operators in the catering and related services industry, today released its consolidated results for FY 2015-2016, corresponding to the twelve months ended September 30, 2016. Commenting on these results, Philippe Salle, the Group’s Chairman and Chief Executive Officer, stated: "One year after the launch of our 2020 strategy, we are ahead of schedule in execution, both in terms of external growth and the Group's transformation process. We achieved our financial objectives for FY 2015-2016, with organic growth of 3.1% (excluding the impact of voluntary contract exits which mainly affected contract catering), and EBITDA margin up by 20 basis points (without the dilutive effect of our most recent acquisition in the United States). And this increase in profitability is just the beginning. Going forward, we intend to continue our drive to optimize operational performance across our various markets through the rollout of the 8 projects under the Tsubaki transformation plan. We therefore expect to see more rapid profitability growth for the current fiscal year and are confident in the Group's longer term outlook." Business development was buoyant in FY 2015-2016. The retention rate for contract catering was 93% at September 30, 2016, having risen steadily throughout the fiscal year despite the effect of the review of the contract portfolio, which mainly concerned France and Italy. A number of major contracts were won in the contract catering & services business line during the fourth quarter, including with Natixis, the Pont d’Issy inter-company restaurant and Cochin hospital in France, Four Seasons Health Care and Murrayfield Stadium in the United Kingdom, Indiana DMHA in the United States, numerous municipal schools in Spain, and Innova and Metro Cash & Carry in Italy. Consolidated revenue totaled €5,896 million in FY 2015-2016. The 3.9% year-on-year increase reflects (i) organic growth of 1.4% (taking into account the 1.7% negative effect of voluntary contract exits), (ii) a positive 2.6% impact from acquisition-led growth, and (iii) a negative 0.2% currency effect. The portion of revenue generated by international operations rose to 52% in FY 2015-2016 from 50% in the previous fiscal year. Contract catering & services revenue was up €233 million, or 5.8%, on the FY 2014-2015 figure, coming in at €4,228 million and accounting for 72% of total Group consolidated revenue. Organic growth was 1.3%, reflecting a positive calendar effect but also the adverse impact of the Group's strategy of withdrawing from low- and non-profit-making contracts in Europe. Excluding voluntary contract exits, organic growth came to 3.4%. The acquisitions carried out in the United States and the United Kingdom4 had a €200 million favorable effect during FY 2015-2016, and net of the impact of the sale of non-strategic operations in the education market, changes in the scope of consolidation pushed up contract catering & services revenue by an overall 4.6%. The currency effect during the year was a negative 0.1%. In France, organic growth was up 2.0% and revenue totaled €2,163 million. Revenue for the international segment advanced 11.1% to €2,065 million. Organic growth for this segment was 0.6%, mainly due to the unfavorable effect of voluntary contract exits in Europe. Acquisitions in the United States and the United Kingdom generated additional growth of 10.7% during the year, whereas the currency effect was a negative 0.3%. Concession catering revenue edged back to €1,668 million in FY 2015-2016 and represented 28% of total Group consolidated revenue. Organic growth came to 1.7% but changes in the scope of consolidation and exchange rates had negative impacts of 2.0% and 0.3% respectively. Revenue generated in France amounted to €657 million, down 8.2% on FY 2014-2015, with changes in the scope of consolidation accounting for 1.8 % of the overall year-on-year contraction. In the international segment, 5.0% growth drove revenue up to €1,011 million for FY 2015-2016. Organic growth was 7.7% but changes in the scope of consolidation and exchange rates trimmed revenue by 2.2% and 0.6% respectively. Consolidated EBITDA5 rose by €26 million to €501 million and represented 8.5% of revenue (or 8.6% excluding the dilutive effect of the consolidation of Preferred Meals in the United States, up 20 basis points on FY 2014-2015). EBITDA5 for the contract catering & services business line increased to €325 million from €304 million and represented 7.7% of revenue, up 10 basis points. Concession catering EBITDA5 amounted to €183 million (versus €179 million in FY 2014-2015) and represented 11.0% of revenue, up 30 basis points year on year. Recurring operating profit (EBIT6) totaled €331 million in FY 2015-2016, up 7.1% year on year, in line with the rise in EBITDA. The EBIT figure includes €13 million in acquisitions intangible asset amortization (versus €8 million in FY 2014-2015). Non-recurring items represented a net expense of €50 million, breaking down as follows: (i) an aggregate €35 million in restructuring costs recorded in France, Italy, Spain and the United States, (ii) €9 million in losses on sales of non-strategic assets and closures of non-profit making sites, and (iii) €5 million in acquisition-related costs. These amounts reflect the acceleration during the year of the implementation of the Group’s acquisition strategy and the measures put in place under the Tsubaki transformation plan. At €63 million, net financial expense was considerably lower than in FY 2014-2015, primarily due to (i) the debt refinancing carried out in December 2014, May 2015 and May 2016, (ii) the better financial conditions obtained for the Group's euro-denominated senior debt in December 2015, and (iii) lower interest rates. The FY 2015-2016 figure also includes €14 million in non-recurring expenses arising on the early redemption in May 2016 of the Group’s high yield notes. The Group's income tax expense rose to €74 million from €68 million and the applicable tax rate was 34%, including the CVAE contribution. The year-on-year decrease in the tax rate was mainly due to lower effective tax rates in certain countries (notably Italy, as a result of the reform of the IRAP regional tax). The Group reported a €6 million loss for the period from discontinued operations, primarily relating to non-strategic operations run by Areas in Northern Europe. Attributable profit for the period advanced 26% to €135 million in FY 2015-2016 and adjusted earnings per share 7 jumped 31% to €1.05. Free cash flow8 contracted by €15 million to €173 million. This reflects the fact that the effects of the higher EBITDA figure and improved working capital before acquisitions were offset by the adverse impact on working capital of acquisitions carried out during the year, a slight rise in capital expenditure and a one-off €21 million tax payment related to prior years (which had been provisioned at September 30, 2015). Excluding non-recurring items and one-off tax payment, the conversion rate from EBITDA into free cash flow stood at 51%, against 58% in FY 2014-2015. Net debt totaled €1,706 million at September 30, 2016, up €254 million on the September 30, 2015 figure, mainly due to the acquisitions carried out during the year for an aggregate amount of €277 million. These acquisitions corresponded to companies and assets (Cura Hospitality, ABL Management, Preferred Meals, Waterfall Catering Group and Autogrill's assets in railway stations in France) as well as long-term equity investments (Ducasse, start-ups etc.). The Group's leverage ratio9 stood at 3.2x EBITDA at September 30, 2016, compared with 3.0x one year earlier. As part of its 2020 strategy, the Group has embarked on a transformation process with a view to accelerating its development. Having set up and launched various Group-wide projects during the plan's first year of implementation, FY 2016-2017 should see an acceleration in the profitable growth momentum created in FY 2015-2016. Consequently, the Group's objectives for FY 2016-2017 are to achieve the following: On November 21, 2016, Elior Group announced its entry into the Indian market through the simultaneous acquisitions of MegaBite Food Services and CRCL, two leading contract caterers in the business & industry market. The Group's new subsidiary – Elior India – will have over 3,500 employees and will serve 135,000 meals per day. This move into India represents the Group's first step towards expanding into emerging markets, which is one of the objectives of its 2020 strategy. India is a highly promising market with significant growth potential and a very fragmented profile. Thanks to these two acquisitions, Elior Group will be a market leader from the outset in India. A conference will be held on Friday, December 9, 2016 at 9.30 a.m. (CET), which will also be accessible by webcast on the Elior Group website and by phone by dialing one of the following numbers: Appendix 1: Revenue by business line and geographic region Appendix 2: Revenue by geographic region Appendix 3: Revenue by market Appendix 4: EBITDA by business line and geographic region Appendix 5: EBITA by business line and geographic region Appendix 6: Simplified cash flow statement Appendix 7: Consolidated financial statements The English-language version of this document is a free translation from the original, which was prepared in French. All possible care has been taken to ensure that the translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. Founded in 1991, Elior Group has grown into one of the world's leading operators in the catering and support services industry, and is now a benchmark player in the business & industry, education, healthcare, and travel markets. Now operating in 15 countries, the Group generated €5,896 million in revenue through 23,000 restaurants and points of sale in FY 2015-2016. Our 120,000 employees serve 4.4 million customers on a daily basis, taking genuine care of each and every one by providing personalized catering and service solutions to ensure an innovative customer experience. We place particular importance on corporate social responsibility and have been a member of the United Nations Global Compact since 2004. The professional excellence of our teams, as well as their unwavering commitment to quality and innovation and to providing best in-class service is embodied in our corporate motto: "Time savored". For further information please visit our website: http://www.eliorgroup.com or follow us on Twitter: @Elior_Group 1. Organic growth: change in revenue on a constant Group structure basis and excluding the currency effect. 2. Changes in scope of consolidation correspond to the acquisitions carried out in the United States and the United Kingdom and completed or planned divestments of non-strategic assets. 3. The currency effect stems from changes in the USD, GBP, MXN and CLP exchange rates. 1. Organic growth: change in revenue on a constant Group structure basis and excluding the currency effect. 2. Changes in scope of consolidation correspond to the acquisitions carried out in the United States and the United Kingdom and completed or planned divestments of non-strategic assets. 3. The currency effect stems from changes in the USD, GBP, MXN and CLP exchange rates. 1. Organic growth: change in revenue on a constant Group structure basis and excluding the currency effect. 2. Changes in scope of consolidation correspond to the acquisitions carried out in the United States and the United Kingdom and completed or planned divestments of non-strategic assets. 3. The currency effect stems from changes in the USD, GBP, MXN and CLP exchange rates. NB: The figures for the first nine months of FY 2015-2016 have been restated due to the reclassification of non-strategic assets held by Areas Northern Europe as discontinued operations. 4. Excluding the impact of stock options and performance shares. 5. Excluding the impact of stock options and performance shares. 6. Excluding the impact of stock options and performance shares. 7. Excluding the impact of stock options and performance shares. 1 Excluding the impact of stock options and performance shares. 2 Adjusted for (i) non-recurring operating items net of tax (at the standard rate of 34%), and (ii) acquisitions intangibles amortization. 3 Preferred Meals, a U.S. company acquired by the Group and consolidated since July 1, 2016. 4 Starr Catering Group and Cura Hospitality (consolidated since October 1, 2015), ABL Management (consolidated since December 1, 2015), Preferred Meals (consolidated since July 1, 2016) and Waterfall Catering Group (consolidated since September 1, 2016). 5 Excluding the impact of stock options and performance shares 6 Including share of profit of equity-accounted investees 7 Adjusted for (i) non-recurring operating items net of tax (at the standard rate of 34%), and (ii) acquisitions intangibles amortization. 8 Defined as EBITDA + change in WCR - net capex - cash impact of tax - non-recurring cash items. 9 Calculated in accordance with the definition in the SFA: Consolidated net debt/Pro forma EBITDA adjusted for acquisitions and divestments carried out in the past twelve months. 10 Excluding changes in scope of consolidation and the currency effect. 11 Excluding the impact of stock options and performance shares. 12 Adjusted for (i) non-recurring operating items net of tax (at the standard rate of 34%), and (ii) acquisitions intangibles amortization.


For the audio version of today's news release please visit http://nexoptic.com/investors/news/ NexOptic Technology Corp. ("NexOptic") ( : NXOPF) (TSX VENTURE: NXO) ( : E301) ( : E301) and Spectrum Optix Inc. of Calgary, Canada ("Spectrum,") and together with NexOptic, the "Companies") are pleased to announce that NexOptic has been selected for inclusion in the 2017 TSX Venture 50®, a ranking of the top performers on the TSX Venture Exchange. NexOptic is ranked second overall in the technology sector. "Our shareholders along with our diverse team of professionals made this distinction possible. We are all honoured to be recognized by the TSX Venture Exchange in this manner." stated Paul McKenzie, CEO of NexOptic. He continued: "The many accomplishments we've achieved are now the strong foundation from which we intend to keep building." The 2017 TSX Venture 50® is a ranking of top performers on the TSX Venture Exchange. These companies have shown results in key measures of market performance. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. On average, these companies have delivered a market cap change of 542% in 2016. The shares of these companies also enjoy a liquid market, with a total of 2.4 billion shares trading over the course of 2016. NexOptic further announces that approximately 64% of outstanding warrants having been issued at three separate intervals and strike prices since February of 2015 have subsequently been exercised. Total proceeds from these exercises are $2,875,613. The Company currently has 64,353,706 shares issued and outstanding. Please visit www.sedar.com and/or NexOptic's website www.nexoptic.com to view our financial statements and to find additional information on NexOptic's share structure. NexOptic is pleased to be joining the Four Points by Sheraton, Nestle Pure Life and other global and regional brands in sponsoring the 2017 Bangkok International Rugby Tens. This annual tournament hosts over 100 men, women and children's teams from around the world and is expected to be televised into over 50,000 homes throughout several Asian markets. The proceeds from this non-profit event support the Nak Suu Rugby Academy of Bangkok, Thailand which encourages and educates at risk children in positive life choices, values, and skills. The tournament commences on February 24th, 2017. Further to the Companies joint news release issued on April 12, 2016, Spectrum Optix received a non-repayable financial contribution of up to $50,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). The Companies are grateful for having been supported and recognized in such a manner by the Government of Canada. For further information on the Top Ranking TSX 50 Recipients, please visit www.tsxventure50.com NexOptic is a publicly traded company, which has an option to acquire, in the aggregate, 100% of Spectrum Optix Inc., a private corporation. The Companies are, in essence, working as a single corporation at this time, with their respective CEOs sitting on each other's boards of directors. Please see NexOptic's news release dated November 18, 2014 for additional details regarding this relationship. Spectrum is developing technologies relating to imagery and light concentration applications. Utilizing its patent-pending Blade Optics™ technology, which contains flat lenses, the company aims to disrupt conventional lens and image capture-based systems. Spectrum is currently in the final stage of completing its proof of concept digital telescope prototype that will utilize its patent pending Blade Optics™ technology, other optical elements and electronic components. The prototype is intended to demonstrate the marketable features of Spectrum's Blade Optics™ technology and its potential to serve as a platform to be used in various optical applications. The Companies' believe that Blade Optics™ has the potential to breakdown many of the limitations associated with conventional, curved lens stacks, including: NexOptic trades on the OTCQB under the symbol "NXOPF," on the TSX Venture as "NXO," on Frankfurt as "E301" and Berlin as "E301." More information is available at www.nexoptic.com On behalf of the Boards of Directors This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws, including, but not limited to, statements with respect to expectations concerning the development of its technology, the development of the prototype, the potential applications of Spectrum's technologies and the technology's potential market impacts. The reader is cautioned that forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other factors which are difficult to predict and that may cause actual results or events to differ materially from those anticipated in such forward looking statements. Forward looking statements are based on the then current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Companies operate and are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations, including, among others: risks commonly associated with the development of new technologies, including that the prototype development is at an early stage and additional work will be required to confirm potential applications and feasibility of Spectrum's technologies; the Companies may not be able complete the prototype as currently expected; the potential applications are based on limited studies and may not be representative of the broader market; the risk that the prototype may not achieve results expected by the Companies; the Companies may not be able to commercialize their technology even if the prototype is successful; NexOptic may not have access to necessary financing on acceptable terms or at all, including, in order to exercise the options under NexOptic's formal agreement with Spectrum and its shareholders or the conditions to NexOptic's options to acquire Spectrum shares may not be otherwise satisfied; and other risks inherent with the patent process, transactions of this type and the business of Spectrum and/or NexOptic. Such forward looking statements should therefore be construed in light of such factors. Other than in accordance with its legal or regulatory obligations, NexOptic is not under any obligation and it expressly disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.


MOU with US National Lab Follows Canadian Government Grant Supporting Amy's EV Battery Recycling Work VANCOUVER, BC / ACCESSWIRE / March 2, 2017 / Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. ("American Manganese" or "AMI" or the "Company") (TSX-V: AMY; OTC PINK: AMYZF; Frankfurt: 2AM), is pleased to announce that the Company has entered into a Memorandum of Understanding ("MOU") with Ames Laboratory, a U.S. Department of Energy National Laboratory, operated by Iowa State University. Ames is the lead national laboratory for the Critical Materials Institute, a U.S. Department of Energy Innovation hub established by Congress in 2013. The Agreement allows both parties to share an interest in collaborating in the area of materials science to synergistically augment the scope and expertise of each organization and to enhance the technological development of both organizations; Both parties recognize that the recovery and reclamation of metals and minerals from spent lithium-ion batteries represents a significant source of critical materials; and Both parties share an interest in collaborating in the exploration of electric vehicle (EV) battery materials recycling options from spent electric vehicle lithium ion batteries having cathode chemistries such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, and Lithium-Manganese. The MOU with the U.S. Government's Ames Lab follows last month's award to American Manganese from the Canadian Government's National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for the continued development of the Company's spent electric vehicle battery cathode materials recycling technology. Ames Laboratory is a U.S. Department of Energy Office of Science national laboratory operated by Iowa State University. Ames Laboratory creates innovative materials, technologies, and energy solutions using its expertise, unique capabilities, and interdisciplinary collaborations to solve global problems. The Critical Materials Institute is a Department of Energy Innovation Hub led by the U.S. Department of Energy's Ames Laboratory. CMI seeks ways to eliminate and reduce reliance on rare-earth metals and other materials critical to the success of clean energy technologies. American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries. Interest in the Company's patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become an industry leader in the recycling of spent electric vehicle lithium ion batteries having cathode chemistries, such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, Lithium-Cobalt-Aluminum, and Lithium-Manganese (Please see the Company's January 19, 2016 press release for further details). On behalf of Management AMERICAN MANGANESE INC. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements," which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.


News Article | January 25, 2017
Site: globenewswire.com

VANCOUVER, British Columbia, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Dr. Stephen Campbell, Principal Scientist at Nano One Materials (TSX-V:NNO) (Frankfurt:LBMB) (OTCBB:NNOMF), today announced an innovation that significantly increases throughput and further decreases the cost of Nano One’s process for the fabrication of lithium ion battery materials. This is new Intellectual Property that also improves the performance of resulting materials and it has been filed provisionally with the U.S. Patent Office. “This is an important enhancement to our processing technology that will reduce capital costs, processing steps and operating costs of our production size plants,” said Dr. Campbell. “We have also seen improved battery performance from the resulting cathode materials.” To view an enhanced version of this image [Initial discharge curves showing improved performance of High Voltage Spinel (LiNi Mn O ) using Nano One’s advanced process.], please visit: http://orders.newsfilecorp.com/files/3606/24708_a1485306669584_29.jpg Preliminary cell data shown here indicates increased power for Cobalt Free, High Voltage Spinel made with this new process. “This innovation also applies to the fabrication of the full range of lithium ion cathode materials, including spinels, lithium iron phosphates (LFP) and all formulations of nickel manganese cobaltate (NMC),” added Dr. Campbell. “We expect to boost capacity of the pilot plant that is under construction, which we will then be able to demonstrate to strategic interests looking for technology, cost and performance advantages.” This improvement builds on previously issued patents and it expands the company’s intellectual property portfolio. It was filed as a Provisional U.S. Patent Application directed to advances in the proprietary process for the fabrication of nanopowders for lithium ion battery (LIB) cathodes. These technology advances were developed with the ongoing support of National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) under the Cobalt Free High Voltage Spinel project announced on June 30, 2016. “We are grateful for IRAP’s support,” said CEO Dan Blondal. “I also want to thank the Nano One team for their dedication and innovative approach. This is a substantial development that adds considerable value to our core processing technology. I look forward to seeing it in action as we ramp up demonstrations of the pilot plant in 2017.” For information with respect to Nano One or the contents of this news release, please contact John Lando (President) at (604) 669-2701 or visit the website at www.nanoone.ca. Nano One Materials Corp (“Nano One” or “the Company”) is developing novel and scalable processing technology for the low-cost production of high performance battery materials used in electric vehicles, energy storage and consumer electronics. The patented technology can be configured for a wide range of nanostructured materials and has the flexibility to shift with emerging and future battery market trends and a diverse range of other growth opportunities. The novel three-stage process uses equipment common to industry and is being engineered for high volume production and rapid commercialization. Nano One’s mission is to establish its patented technology as a leading platform for the global production of a new generation of nanostructured composite materials. For more information, please visit www.nanoone.ca National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) is Canada’s premier innovation assistance program for small and medium-sized enterprises. For over 60 years, IRAP has been stimulating wealth creation for Canada through technological innovation. This is largely accomplished by providing technology assistance and financial support to small and medium-sized enterprises at all stages of the innovation process, to build their innovation capacity. IRAP helps small and medium-sized enterprises understand the technology issues and opportunities and provides linkages to the best expertise in Canada. http://www.nrc-cnrc.gc.ca/eng/irap/index.html Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the actual receipt of the grant monies, the execution of the Company’s plans which are contingent on the receipt of such monies and the commercialization of the Company’s technology and patents. Generally, forward-looking information can be identified by the use of forward-looking terminology such as 'believe', 'expect', 'anticipate', 'plan', 'intend', 'continue', 'estimate', 'may', 'will', 'should', 'ongoing', or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the completion of final documentation with SDTC and the receipt of all necessary regulatory approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE


VANCOUVER, BC--(Marketwired - February 14, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) ( : AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has completed the treatment phase of its multi-dose Proof of Concept clinical trial evaluating the bioavailability and safety of its once-weekly transdermal patch for aripiprazole, AQS1301. Aripiprazole is an atypical antipsychotic and the active ingredient in Abilify®, a leading medication in the US used for the treatment of a number of psychiatric disorders including bipolar I disorder, schizophrenia, major depressive disorder and irritability associated with autistic disorder. Aequus' novel once-weekly formulation is designed to provide patients with an easy to use and convenient long-acting alternative to the once a day oral pill. The Company expects to report topline results from this multi-dose study in the first quarter of 2017. "We look forward to announcing the results of this study, which we expect will provide a solid basis for advancing AQS1301 through an initial meeting with the FDA regarding the clinical path to approval in the United States, as well as continued advancement in partnership discussions for this program," said Anne Stevens, COO and Director of Aequus. "The single-dose exposure study previously completed in 2016 demonstrated the potential for our formulation to provide sustained and controlled delivery of aripiprazole over seven days in therapeutic doses. This study will provide information that will enable us and our development partner, Corium International, to finalize the design of the transdermal patch that we would advance into late stage clinical studies." This 28-day, multi-dose Proof of Concept study was supported by a grant of up to $100,000 from the National Research Council of Canada Industrial Research Assistance Program ("NRC-IRAP"). Aequus anticipates meeting with the US FDA following the results of this study for a pre-Investigational New Drug (pre-IND) meeting to define the clinical strategy for regulatory approval in the US. After meeting with the FDA, Aequus expects to select potential partners to further develop the product and to commercialize the product, once approved. Aripiprazole is an atypical antipsychotic, currently available in once-daily oral tablets and a once-monthly injectable form, however, medication adherence continues to be a significant challenge for patients. Aequus has developed and owns global rights to a seven-day patch application of aripiprazole intended to provide patients with a convenient and easy to use long acting alternative, in an effort to reduce the rate of relapse that may result from patients not adhering to their prescribed dosing schedule. Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) ( : AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' development stage pipeline includes several products in neurology, psychiatry and women's health with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca. This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "potential" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the implementation of our business model and strategic plans, the initiation and parameters of the Phase I clinical trial, the completion of the analysis of the Phase I clinical trial and the next steps in connection therewith. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions and the anticipated results of the Phase I clinical trial. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading "Risk Factors" in the Company's Short-Form Prospectus dated June 30, 2015, a copy of which is available on Aequus' profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus' SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. Abilify® is a registered trademark of Otsuka Pharmaceutical Co., Ltd.


The Agreement allows both parties to share an interest in collaborating in the area of materials science to synergistically augment the scope and expertise of each organization and to enhance the technological development of both organizations; Both parties recognize that the recovery and reclamation of metals and minerals from spent lithium-ion batteries represents a significant source of critical materials; and Both parties share an interest in collaborating in the exploration of electric vehicle (EV) battery materials recycling options from spent electric vehicle lithium ion batteries having cathode chemistries such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, and Lithium-Manganese. The MOU with the U.S. Government's Ames Lab follows last month's award to American Manganese from the Canadian Government's National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for the continued development of the Company's spent electric vehicle battery cathode materials recycling technology. Ames Laboratory is a U.S. Department of Energy Office of Science national laboratory operated by Iowa State University. Ames Laboratory creates innovative materials, technologies, and energy solutions using its expertise, unique capabilities, and interdisciplinary collaborations to solve global problems. The Critical Materials Institute is a Department of Energy Innovation Hub led by the U.S. Department of Energy's Ames Laboratory. CMI seeks ways to eliminate and reduce reliance on rare-earth metals and other materials critical to the success of clean energy technologies. American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries. Interest in the Company's patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become an industry leader in the recycling of spent electric vehicle lithium ion batteries having cathode chemistries, such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, Lithium-Cobalt-Aluminum, and Lithium-Manganese (Please see the Company's January 19, 2016 press release for further details). On behalf of Management AMERICAN MANGANESE INC. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements," which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.


EDMONTON, Alberta , Jan. 16, 2017 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. announced they have received non-refundable financial contribution from the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP). In addition to technical and business advisory services provided by NRC-IRAP, the funding is being used to develop a pipeline of antimicrobial product candidates. The company is currently conducting studies on a family of antimicrobial compounds with the goal of selecting one or more candidates from this family to advance into preclinical studies in 2017. “Our aim at Fedora is to apply our scientific acumen to the challenge of antimicrobial resistance (AMR),” stated Christopher G. Micetich, founder and chief executive officer of Fedora Pharmaceuticals. “Our first effort focused on the development of a family of beta-lactamase inhibitors that showed promise against all four classes of beta-lactamases and was licensed by Roche in 2015 for further development. Building on that success, we have begun development of a pipeline of antimicrobial candidates to address the incredible need that still exists in the treatment of drug-resistant bacterial and fungal infections.” Mr. Micetich continued, “Our efforts align closely with the goals of the Government of Canada which are committed to addressing AMR through surveillance, stewardship, prevention and innovation. We are dedicated to working with government organization as well as partners in the pharmaceutical industry to develop new products to treat AMR infections.” Fedora Pharmaceuticals is developing a pipeline of antimicrobial drug candidates designed to have activity against multi-drug resistant pathogens. Fedora previously developed a family of beta-lactamase inhibitors that was licensed by Roche in January 2015 from Meiji Seika Pharma and Fedora Pharmaceuticals. Under the terms of the agreement, Meiji and Fedora will receive upfront plus development, regulatory and sales event milestone payments totaling potentially up to $750 million. In addition, Meiji and Fedora are entitled to receive tiered royalties on sales of products originating from this collaboration. Fedora was founded in 2012 and is headquartered in Edmonton, Alberta, Canada. In 2015, the company received the Alberta Life Sciences’ "Company of the Year" award and the Alberta Science and Technology Leadership (ASTech) Foundation’s award for Outstanding Commercial Achievement. For more information, please visit Fedora Pharmaceutical’s website at www.fedorapharma.com.


GPURE Variants Target Markets for Waste Water Filtration and Large Area Nanofiltration Systems; Gas Separation and Sensors, and; Varnishes for Wood Surfaces Among Other Potential Applications KINGSTON, ONTARIO--(Marketwired - Feb. 16, 2017) - Grafoid Inc., a graphene R&D and investment company announced today its development of the GPURE Membrane Platform consisting initially of six next generation GPURE Graphene-Polymer membrane technologies intended for industrial markets. Grafoid's largest shareholder is Focus Graphite Inc. (TSX VENTURE:FMS)(OTCQX:FCSMF)(FRANKFURT:FKC), owner of the Lac Knife high-grade flake graphite deposit in Quebec. Focus Graphite holds two off-take agreements with Grafoid to supply it with high-purity graphite for graphene application commercialization with joint venture partners. Grafoid's GPURE technologies span a range of scalable industrial applications requiring novel, disruptive solutions to create new products or enhance or supplant existing membrane technologies. One of the key obstacles to graphene's broad, universal industrial acceptance is the absence to date of low-cost, high performing graphene applications that can be successfully adapted for use across all industrial sectors. Market and Markets Research anticipates the global membranes market will grow significantly by 2020 with water & wastewater treatment, pharmaceuticals & medical segments accounting for approximately two-thirds of the global membranes market. It reported that "the increasing use of membranes in the oil & gas sector for gas processing, hydrogen production, carbon dioxide removal from natural gas streams, and so on are also projected to drive the growth in the membranes market." GPURE (B) - A stable, large area membrane developed for wastewater filtration suitable for very high temperature operating applications GPURE (C) - A large area free-standing membrane developed for water filtration pre-treatment and may be suitable for use in gas separation applications and may be used as a lightweight component for automotive and sports equipment applications GPURE (D) - A large area membrane that may be used for gas separation and sensing applications GPURE (E) - A large area membrane intended for use in gas separation applications GPURE (F)- May be applied as a graphene varnish for wood surfaces to protect against moisture, UV light and high temperatures Grafoid Chief Executive Officer Gary Economo said the company's next generational technology developments could lead to new products that create both operating and economic efficiencies that are critical for sustainable growth. Grafoid is engaged with over 25 companies in Asia, Europe and North America, who are currently testing our materials for use in one or more of their product applications. If their testing returns positive results, there is a potential to develop joint venture partnerships or licensing agreements. More detailed information on the Company's individual GPURE products and potential applications will be released in the coming weeks. Grafoid is focused on three areas of graphene-related technology development it sees as "low-hanging fruit" for industrial adoption. They are graphene based materials for energy creation, storage and transmission; graphene based polymers and; graphene coatings for all industrial sectors. Grafoid is a graphene R&D and investment company. The company provides expertise as well as product and processes for transformative, industrial-scale graphene applications in partnership with leading corporations and institutions around the world. A privately held Canadian corporation, Grafoid invests in graphene applications and economically scalable production processes for graphene and graphene derivatives from raw, unprocessed graphite ore. Focus Graphite Inc. holds a significant interest in Grafoid Inc. Incorporated in 2011, Grafoid's global enterprise platform includes 17 subsidiary companies engaged in the development of Mesograf™ materials and products, and GrafeneX ultra-thin graphene industrial coatings and commercialization development services. They include, but are not limited to: Mesograf™-enhanced lithium batteries for electric vehicles, consumer electronics, and industrial energy storage; polymers, plastics, rubber, elastomers, and composite materials; fiber science including aluminum alloys; lubricants; fire retardant materials; thermal management solutions; EMI/RFI/EMP shielding; solar solutions, and analytical testing, and; laboratory services. Grafoid's research is supported through the Industrial Research Assistance Program (IRAP) of the National Research Council of Canada, and, on February 20, 2015, Grafoid received an $8.1 million investment from the SD Tech Fund™ of Sustainable Development Technology Canada (SDTC) to develop a technology that will automate Mesograf™ graphene production and end-product development. SDTC is mandated by the Government of Canada to support clean technology companies as they move their technologies to market. For more information about Grafoid, please visit http://www.grafoid.com


News Article | November 3, 2016
Site: phys.org

Iron-nickel meteorites are a common class of space rocks found on Earth, and previous examples have been seen on Mars, but this one, called "Egg Rock," is the first on Mars examined with a laser-firing spectrometer. To do so, the rover team used Curiosity's Chemistry and Camera (ChemCam) instrument. Scientists of the Mars Science Laboratory (MSL) project, which operates the rover, first noticed the odd-looking rock in images taken by Curiosity's Mast Camera (Mastcam) at at a site the rover reached by an Oct. 27 drive. "The dark, smooth and lustrous aspect of this target, and its sort of spherical shape attracted the attention of some MSL scientists when we received the Mastcam images at the new location," said ChemCam team member Pierre-Yves Meslin, at the Research Institute in Astrophysics and Planetology (IRAP), of France's National Center for Scientific Research (CNRS) and the University of Toulouse, France. ChemCam found iron, nickel and phosphorus, plus lesser ingredients, in concentrations still being determined through analysis of the spectrum of light produced from dozens of laser pulses at nine spots on the object. The enrichment in both nickel and phosphorus at some of the same points suggests the presence of an iron-nickel-phosphide mineral that is rare except in iron-nickel meteorites, Meslin said. Iron meteorites typically originate as core material of asteroids that melt, allowing the molten metal fraction of the asteroid's composition to sink to the center and form a core. "Iron meteorites provide records of many different asteroids that broke up, with fragments of their cores ending up on Earth and on Mars," said ChemCam team member Horton Newsom of the University of New Mexico, Albuquerque. "Mars may have sampled a different population of asteroids than Earth has." In addition, the study of iron meteorites found on Mars—including examples found previously by Mars rovers—can provide information about how long exposure to the Martian environment has affected them, in comparison with how Earth's environment affects iron meteorites. Egg Rock may have fallen to the surface of Mars many millions of years ago. Researchers will be analyzing the ChemCam data from the first few laser shots at each target point and data from subsequent shots at the same point, to compare surface versus interior chemistry. Egg Rock was found along the rover's path up a layer of lower Mount Sharp called the Murray formation, where sedimentary rocks hold records of ancient lakebed environments on Mars. The main science goal for Curiosity's second extended mission, which began last month, is to investigate how ancient environmental conditions changed over time. The mission has already determined that this region once offered conditons favorable for microbial life, if any life ever existed on Mars. Curiosity was launched five years ago this month, on Nov. 26, 2011, from Cape Canaveral Air Force Station, Florida. It landed inside Gale Crater, near the foot of Mount Sharp, in August 2012. The rover remains in good condition for continuing its investigations, after working more than twice as long as its originally planned prime mission of about 23 months, though two of its 10 science instruments have recently shown signs of potentially reduced capability. The neutron-generating component of Curiosity's Dynamic Albedo of Neutrons (DAN) instrument, designed for working through the prime mission, is returning data showing reduced voltage. Even if DAN could no longer generate neutrons, the instrument could continue to check for water molecules in the ground by using its passive mode. The performance of the wind-sensing capability from Curiosity's Rover Environmental Monitoring Station (REMS) is also changing, though that instrument still returns other Mars-weather data daily, such as temperatures, humidity and pressure. Analysis is in progress for fuller diagnosis of unusual data from DAN, which was provided by Russia, and REMS, provided by Spain. Explore further: Curiosity finds a melted space metal meteorite on the surface of Mars


GPURE Variants Target Markets for Waste Water Filtration and Large Area Nanofiltration Systems; Gas Separation and Sensors, and; Varnishes for Wood Surfaces Among Other Potential Applications KINGSTON, ONTARIO--(Marketwired - Feb. 16, 2017) - Grafoid Inc., a graphene R&D and investment company announced today its development of the GPURE Membrane Platform consisting initially of six next generation GPURE Graphene-Polymer membrane technologies intended for industrial markets. Grafoid's GPURE technologies span a range of scalable industrial applications requiring novel, disruptive solutions to create new products or enhance or supplant existing membrane technologies. One of the key obstacles to graphene's broad, universal industrial acceptance is the absence to date of low-cost, high performing graphene applications that can be successfully adapted for use across all industrial sectors. Market and Markets Research anticipates the global membranes market will grow significantly by 2020 with water & wastewater treatment, pharmaceuticals & medical segments accounting for approximately two-thirds of the global membranes market. It reported that "the increasing use of membranes in the oil & gas sector for gas processing, hydrogen production, carbon dioxide removal from natural gas streams, and so on are also projected to drive the growth in the membranes market." GPURE (B) - A stable, large area membrane developed for wastewater filtration suitable for very high temperature operating applications GPURE (C) - A large area free-standing membrane developed for water filtration pre-treatment and may be suitable for use in gas separation applications and may be used as a lightweight component for automotive and sports equipment applications GPURE (D) - A large area membrane that may be used for gas separation and sensing applications GPURE (E) - A large area membrane intended for use in gas separation applications GPURE (F)- May be applied as a graphene varnish for wood surfaces to protect against moisture, UV light and high temperatures Grafoid Chief Executive Officer Gary Economo said the company's next generational technology developments could lead to new products that create both operating and economic efficiencies that are critical for sustainable growth. Grafoid is engaged with over 25 companies in Asia, Europe and North America, who are currently testing our materials for use in one or more of their product applications. If their testing returns positive results, there is a potential to develop joint venture partnerships or licensing agreements. More detailed information on the Company's individual GPURE products and potential applications will be released in the coming weeks. Grafoid is focused on three areas of graphene-related technology development it sees as "low-hanging fruit" for industrial adoption. They are graphene based materials for energy creation, storage and transmission; graphene based polymers and; graphene coatings for all industrial sectors. Grafoid is a graphene R&D and investment company. The company provides expertise as well as product and processes for transformative, industrial-scale graphene applications in partnership with leading corporations and institutions around the world. A privately held Canadian corporation, Grafoid invests in graphene applications and economically scalable production processes for graphene and graphene derivatives from raw, unprocessed graphite ore. Focus Graphite Inc. holds a significant interest in Grafoid Inc. Incorporated in 2011, Grafoid's global enterprise platform includes 17 subsidiary companies engaged in the development of Mesograf™ materials and products, and GrafeneX ultra-thin graphene industrial coatings and commercialization development services. They include, but are not limited to: Mesograf™-enhanced lithium batteries for electric vehicles, consumer electronics, and industrial energy storage; polymers, plastics, rubber, elastomers, and composite materials; fiber science including aluminum alloys; lubricants; fire retardant materials; thermal management solutions; EMI/RFI/EMP shielding; solar solutions, and analytical testing, and; laboratory services. Grafoid's research is supported through the Industrial Research Assistance Program (IRAP) of the National Research Council of Canada, and, on February 20, 2015, Grafoid received an $8.1 million investment from the SD Tech Fund™ of Sustainable Development Technology Canada (SDTC) to develop a technology that will automate Mesograf™ graphene production and end-product development. SDTC is mandated by the Government of Canada to support clean technology companies as they move their technologies to market. For more information about Grafoid, please visit http://www.grafoid.com

Loading IRAP collaborators
Loading IRAP collaborators